Mariposa Therapeutics Ltd, a Welsh biotech company developing a novel topical treatment for patients with Epidermolysis Bullosa Simplex has appointed Dr Bill Pigg to its Board of Directors. 

“I am really excited to join the team at Mariposa as during my time in wound management I have come into contact with Epidermolysis Bullosa on several occasions and the opportunity to be involved with an organisation who are so strongly focused upon addressing this terrible debilitating disease is such a strong motivator” commented Dr Pigg. 

Bill Pigg has over 30 years’ experience in the MedTech industry with companies such as Johnson and Johnson and Smith and Nephew spanning the New Product Development process from early-stage research to late-stage development and commercialisation. As part of the leadership team at Johnson and Johnson Advanced Wound Care, he was part of the team who successfully spun the company out under private equity forming Systagenix and subsequently sold the business back into corporate ownership under Acelity.

For the last 5 years Bill has operated as a consultant working with academia, SMEs and large MedTechs helping them to enhance their product development practices and capabilities. Bill also sits on the board of three Biotech and MedTech companies.

Lucy Sykes, PhD, Chief Scientific Officer of Mariposa Therapeutics, said “Bill’s experience and expertise in wound care product development are a huge asset to add to our Board of Directors. I am excited to work with him to accelerate the development of our programmes towards the clinic”.